Cargando…
Correction: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021761/ https://www.ncbi.nlm.nih.gov/pubmed/35444063 http://dx.doi.org/10.1136/jitc-2021-003289corr1 |
Ejemplares similares
-
CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022) -
UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA
por: Maich, William, et al.
Publicado: (2023) -
Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023) -
CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets
por: Kashima, Jumpei, et al.
Publicado: (2022) -
Correction: Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
Publicado: (2021)